Genetic
SKG0106
SKG0106 is a genetic therapy with 3 clinical trials. Currently 3 active trials ongoing.
Total Trials
3
Max Phase
—
Type
GENETIC
Molecule
—
Success Metrics
Active Trials
3(100%)
Phase Distribution
Ph phase_1
2
67%
Phase Distribution
2
Early Stage
0
Mid Stage
0
Late Stage
Phase Distribution2 total trials
Phase 1Safety & dosage
2(100.0%)
Highest Phase Reached
Phase 1Trial Status & Enrollment
Completion Rate
0.0%
0 of 0 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
3
trials recruiting
Total Trials
3
all time
Status Distribution
Active(3)
Detailed Status
Recruiting3
Development Timeline
Analytics
Development Status
Total Trials
3
Active
3
Success Rate
N/A
Most Advanced
Phase 1
Trials by Phase
Phase 12 (100.0%)
Trials by Status
recruiting3100%
Recent Activity
3 active trials
Showing 3 of 3
recruitingphase_1
Phase I/II Study of SKG0106 Intravitreal Injection in Patients With Neovascular Age-related Macular Degeneration (nAMD)
NCT05986864
recruitingphase_1
A Clinical Study Evaluating the Safety and Efficacy of SKG0106 in Patients With Neovascular Age-related Macular Degeneration (nAMD)
NCT06213038
recruiting
A Long-term Follow-up Study to Evaluate SKG0106 in the Treatment of Patients With nAMD
NCT06346600
Clinical Trials (3)
Showing 3 of 3 trials
NCT05986864Phase 1
Phase I/II Study of SKG0106 Intravitreal Injection in Patients With Neovascular Age-related Macular Degeneration (nAMD)
NCT06213038Phase 1
A Clinical Study Evaluating the Safety and Efficacy of SKG0106 in Patients With Neovascular Age-related Macular Degeneration (nAMD)
NCT06346600
A Long-term Follow-up Study to Evaluate SKG0106 in the Treatment of Patients With nAMD
All 3 trials loaded
Drug Details
- Intervention Type
- GENETIC
- Total Trials
- 3